Showing results (231-240 of 268) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|September 11, 1986
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogueL K Kvols, C G Moertel, M J O'Connell, et al.
The Journal of the American Board of Family Practice|January 1, 1988
Cost-effectiveness of office obstetrical ultrasound in family practice: preliminary considerationsR G Hahn, S Ho, L D Roi, et al.
American Journal of Clinical Oncology|August 1, 1983
Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinomaJ Rubin, L K Kvols, C G Moertel, et al.
Alcoholism, Clinical and Experimental Research|November 7, 2001
Do ethanol and deuterium oxide distribute into the same water space in healthy volunteers?A Norberg, B Sandhagen, L E Bratteby, et al.
Cancer|May 1, 1988
An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancerE T Creagan, J C Buckner, R G Hahn, et al.
Medical and Pediatric Oncology|January 1, 1978
A preliminary study of cyclophosphamide (NSC-26271), adriamycin (NSC-123127), imidazole carboxamide (NSC-45388), and actinomycin D (NSC-3053) with or without MER-BCG in patients with advanced sarcomasE T Creagan, J H Edmonson, R G Hahn, et al.
JAMA|November 9, 1979
Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysisD A Decker, D L Ahmann, H F Bisel, et al.
American Journal of Clinical Oncology|December 1, 1995
Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group studyM A Gertz, L A Kalish, R A Kyle, et al.
Cancer|April 15, 1982
Primary anterior mediastinal seminomaR D Hurt, J E Bruckman, G M Farrow, et al.
Cancer|January 15, 1989
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanomaD L Ahmann, E T Creagan, R G Hahn, et al.
Pageof 27